{
    "clinical_study": {
        "@rank": "136377", 
        "brief_summary": {
            "textblock": "Patients with superficial transitional cell carcinoma of the bladder will be treated with\n      intravesical suramin in a phase I dose escalating study.  The toxicity of suramin\n      administered in this fashion will be evaluated."
        }, 
        "brief_title": "A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder", 
        "completion_date": "December 2000", 
        "condition": [
            "Bladder Neoplasms", 
            "Carcinoma, Transitional Cell"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder Neoplasms", 
                "Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Transitional Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with superficial transitional cell carcinoma of the bladder will be treated with\n      intravesical suramin in a phase I dose escalating study.  The toxicity of suramin\n      administered in this fashion will be evaluated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n        Histologically confirmed superficial transitional cell carcinoma of the bladder\n        pathologically staged as Tis, Ta, or T1. Visible tumors at time of treatment not required.\n        No metastatic disease or muscle invasion.\n\n        Clinically useful pretreatment bladder function required.\n\n        No significant prostatic obstructive symptoms associated with impaired or incomplete\n        bladder emptying.\n\n        No active urinary tract infection.\n\n        PRIOR/CONCURRENT THERAPY:\n\n        At least 1 course of prior standard intravesical therapy required.\n\n        At least 4 weeks since intravesical treatment, with resolution of any local or systemic\n        toxicity.\n\n        PATIENT CHARACTERISTICS:\n\n        Age: 18 and over.\n\n        Performance status:  ECOG 0 or 1.\n\n        Hematopoietic:\n\n        WBC at least 3,300;\n\n        Hemoglobin at least 10 g/dL.\n\n        Hepatic:\n\n        Bilirubin no greater than 1.5 mg/dL;\n\n        AST and ALT no greater than 2 times normal.\n\n        Renal: Creatinine no greater than 1.5 mg/dL.\n\n        OTHER:\n\n        Medically able to undergo cystoscopy.\n\n        No pregnant women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "18", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001381", 
            "org_study_id": "940098", 
            "secondary_id": "94-C-0098"
        }, 
        "intervention": {
            "intervention_name": "suramin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Suramin"
        }, 
        "keyword": [
            "Adult", 
            "Intravesical Chemotherapy"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Cancer Institute (NCI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "PMID": "1512858", 
                "citation": "Gansler T, Vaghmar N, Olson JJ, Graham SD. Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures. J Urol. 1992 Sep;148(3):910-4."
            }, 
            {
                "PMID": "8738403", 
                "citation": "Walther MM, Figg WD, Linehan WM. Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World J Urol. 1996;14 Suppl 1:S8-11. Review."
            }, 
            {
                "PMID": "7933214", 
                "citation": "Walther MM, Trahan EE, Cooper M, Venzon D, Linehan WM. Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines. J Urol. 1994 Nov;152(5 Pt 1):1599-602."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001381"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "March 1994", 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2000"
    }, 
    "geocoordinates": {
        "National Cancer Institute (NCI)": "38.985 -77.095"
    }
}